These findings underscore the limitations of relying on proteinuria alone to assess LN treatment success and demonstrate the clinical utility of biomarker-guided risk stratification.

Chronic liver disease (CLD) and its advanced stage, cirrhosis, represent a significant global health burden, with portal ...